Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599094 | 0.85 | TSHR (0.39) | TSHRHDAC4HDAC2HDAC8BCHE | |
| SCHEMBL5598833 | 0.84 | DPP4 (0.40) | TSHRACHEDPP4NR1H2NR1H3 | |
| SCHEMBL5598730 | 0.72 | DPP4 (0.38) | TSHRDPP4NR1H2NR1H3SLC25A5 | |
| SCHEMBL7955954 | 0.68 | ACHE (0.50) | ACHE | |
| SCHEMBL8731749 | 0.66 | TSHR (0.64) | TSHR | |
| SCHEMBL202737 | 0.66 | TSHR (0.58) | TSHRHDAC4HDAC2HDAC8ELANE | |
| SCHEMBL526407 | 0.66 | TSHR (0.48) | TSHRHDAC4HDAC2HDAC8ELANE | |
| SCHEMBL2436457 | 0.66 | TSHR (0.38) | TSHR | |
| SCHEMBL2436969 | 0.65 | TSHR (0.40) | TSHR | |
| SCHEMBL14177748 | 0.64 | HDAC4 (0.42) | TSHRHDAC4HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226946-B2 | Substituted phenol compounds useful for anesthesia and sedation | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20050032753-A1 | Substituted phenol compounds useful for anesthesia and sedation | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-10 | — | — | US | disclosed |
| US-6815555-B2 | CONTAINING AN ESTER, ANHYDRIDE, PHOSPHONATE OR THIOESTER GROUP | THERAVANCE, INC. | 2004-11-09 | — | — | US | disclosed |
| EP-1430017-A2 | SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION | Theravance, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030119790-A1 | Substituted phenol compounds useful for anesthesia and sedation | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003026632-A2 | SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION | THERAVANCE, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032753-A1 | Substituted phenol compounds useful for anesthesia and sedation | OPRL1, PNMT, PPARG | TSHR 2222/4885HDAC4 594/4885HDAC2 725/4885 |
| US-20030119790-A1 | Substituted phenol compounds useful for anesthesia and sedation | OPRL1, PNMT, PPARG | TSHR 2222/4885HDAC4 594/4885HDAC2 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.